Immunovia AB (publ) (LON:0G8X)

Market Cap	10.95M +21.4%
Revenue (ttm)	72.26K -7.0%
Net Income	-8.48M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,100,000
Open	0.2230
Previous Close	0.2195
Day's Range	0.2230 - 0.2230
52-Week Range	0.1544 - 0.9250
Beta	2.66
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2026

About Immunovia AB

Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0G8X

Financial Performance

In 2025, Immunovia AB's revenue was 685,000, a decrease of -26.42% compared to the previous year's 931,000. Losses were -145.92 million, 90.6% more than in 2024.

Financial numbers in SEK